QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bmo-capital-reiterates-outperform-on-terns-pharma-raises-price-target-to-26

BMO Capital analyst Etzer Darout reiterates Terns Pharma (NASDAQ:TERN) with a Outperform and raises the price target from $1...

 reported-earlier-terns-pharmaceuticals-prices-upsized-15015m-public-offering-of-11919048-at-1050share

Terns intends to use the net proceeds from the proposed offering, to fund research, clinical trials, development and manufactur...

 jmp-securities-maintains-market-outperform-on-terns-pharma-raises-price-target-to-20

JMP Securities analyst Silvan Tuerkcan maintains Terns Pharma (NASDAQ:TERN) with a Market Outperform and raises the price ta...

 terns-pharmaceuticals-oral-glp-1-reaches-phase-1-finish-line-with-encouraging-weight-loss-data-after-one-month

Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and over...

Core News & Articles

PLTR: 8% | Palantir Technologies shares are trading higher amid its addition to the S&P 500 index. TERN: 42% | Terns Pharma...

 jmp-securities-reiterates-market-outperform-on-terns-pharma-maintains-15-price-target

JMP Securities analyst Silvan Tuerkcan reiterates Terns Pharma (NASDAQ:TERN) with a Market Outperform and maintains $15 pric...

 bmo-capital-reiterates-outperform-on-terns-pharma-maintains-19-price-target

BMO Capital analyst Etzer Darout reiterates Terns Pharma (NASDAQ:TERN) with a Outperform and maintains $19 price target.

 terns-pharma-q2-eps-031-beats-034-estimate

Terns Pharma (NASDAQ:TERN) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.34) ...

 terns-pharmaceuticals-cfo-mark-vignola-to-leave-following-appointment-of-successor-appoints-elona-kogan-as-chief-legal-officer

CEO Amy Burroughs Highlights Kogan's Leadership And Industry Knowledge As Key To Growth; Bryan Yoon To Stay Through Septemb...

 kenneth-griffin-reports-53-passive-stake-in-terns-pharmaceuticals-as-of-july-10

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION